CIK 0001850119 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Century Therapeutics, Inc.
Sign in to watch- Ticker
- IPSC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 842040295
- Phone
- 215-981-4000
- Business address
- 25 N 38TH STREET, 12TH FLOOR, PHILADELPHIA, PA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,212
- in 5 filings
Net −$10,212. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 63 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-11 | Russotti Gregory See Remarks | Grant or award | +120,000 | 392,573 | ||
| 2025-03-11 | Russotti Gregory See Remarks | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2025-03-11 | Farid Adrienne Chief Operations Officer | Grant or award | +120,000 | 251,717 | ||
| 2025-03-11 | Farid Adrienne Chief Operations Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2025-03-11 | Carr Douglas SVP Finance & Operations | Grant or award | +95,625 | 411,181 | ||
| 2025-03-11 | Carr Douglas SVP Finance & Operations | Grant or award · Stock Option (right to buy) | +95,625 | 95,625 | ||
| 2025-03-10 | Pfeiffenberger Brent President and CEO | Sale | −2,235 | $0.62 | $1K | 1,190,310 |
| 2025-03-10 | Russotti Gregory See Remarks | Sale | −2,360 | $0.62 | $1K | 272,573 |
| 2025-03-10 | Farid Adrienne Chief Operations Officer | Sale | −2,359 | $0.62 | $1K | 131,717 |
| 2025-03-10 | Carr Douglas SVP Finance & Operations | Sale | −1,240 | $0.62 | $763 | 315,556 |
| 2025-02-18 | Pfeiffenberger Brent President and CEO | Sale | −34,712 | $0.78 | $27K | 1,192,545 |
| 2025-02-03 | Farid Adrienne Chief Operations Officer | Sale | −1,054 | $0.78 | $822 | 134,076 |
| 2025-02-03 | Carr Douglas SVP Finance & Operations | Sale | −351 | $0.78 | $274 | 316,796 |
| 2024-12-04 | Pfeiffenberger Brent President and CEO | Shares withheld for taxes | −243,447 | $1.44 | $351K | 1,227,257 |
| 2024-11-04 | Farid Adrienne Chief Operations Officer | Sale | −1,033 | $1.23 | $1K | 135,130 |
| 2024-11-04 | Carr Douglas SVP Finance & Operations | Sale | −283 | $1.23 | $347 | 317,147 |
| 2024-11-01 | Carr Douglas SVP Finance & Operations | Shares withheld for taxes | −16,611 | $1.26 | $21K | 317,430 |
| 2024-10-14 | Conn Morgan Chief Finanical Officer | Grant or award | +60,148 | 60,148 | ||
| 2024-10-14 | Conn Morgan Chief Finanical Officer | Grant or award · Stock Option (right to buy) | +360,890 | 360,890 | ||
| 2024-10-01 | Cowan Chad Chief Scientific Officer | Grant or award | +74,376 | 210,806 |
Page 5 of 6 · 118 trades